Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong Dan Shochat?

Dan Shochat

Consultant

KALOBIOS PHARMACEUTICALS INC

HQ Phone:  (650) 243-3100

Direct Phone: (650) ***-**** ext. ***direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

KALOBIOS PHARMACEUTICALS INC

442 Littlefield Avenue

South San Francisco, California,94080

United States

Company Description

KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus o... more.

Find other employees at this company (97)

Background Information

Employment History

Consulting Vice President of Development

Intellect Neurosciences Inc


Director of Biotechnology Development

American Cyanamid Company


Senior Vice President and Chief Scientific Officer

Coulter Pharmaceutical , Inc.


Development

Bexxar


Group Director, Product Research and Development

Immunomedics , Inc.


Vice President of Pharmaceutical Development

Deltagen , Inc.


Visiting Lecturer and Adjunct Professor At the Chemistry Department

Rutgers University


Affiliations

Celscia Therapeutics Inc.

Co-Founder


Biotechnology Development Section

Founder


PROLOR Biotech , Inc.

Scientific Advisory Board Member


Modigene Inc.

Scientific Advisory Board Member


Mindset BioPharmaceuticals Inc

Scientific Advisory Board Member


University of Medicine and Dentistry of New Jersey

Associate Member


Center for Molecular Medicine and Immunology

Founder


ANSTO Inc

Member of the Technical Advisory Committee To the Board of Directors


Education

Bachelor of Science

biology

Hebrew University


Master in Science

physiology

Hebrew University


Ph.D.

Biochemistry

L.S.U. Medical School


Ph.D.

biochemistry

Louisiana State University Medical Center


Web References(20 Total References)


Management Team :: Intellect Neurosciences, Inc

www.intellectns.com [cached]

Dan Shochat, Ph.D.
Vice President Dan Shochat, Ph.D. has more than 28 years of experience in the biotechnology industry and is a pioneer in the antibody development arena. Prior to joining Intellect, he served as vice president of nonclinical development at KaloBios Therapeutics. Prior, he was among the first employees of Immunomedics Inc., Newark, NJ where he served as group director, product R&D. Dr. Shochat is the inventor of several technologies, including that of the approved in vivo tumor-imaging agent CEA-Scan; Mylotarg - the first approved antibody-cytotoxic drug conjugate; and the design, process and formulation for the commercial radiolabeling of the B1 antibody at a 55 Curie scale. The lead product from this work was Bexxar, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma that was approved by the FDA on June 2003. He is co-founder of Celscia Therapeutics Inc. - a therapeutic antibodies development company - which merged with KaloBios Therapeutics in January 2004. From 2001 to 2007 Dr. Shochat was a member of the Technical Advisory Committee to the Board of Directors of the Australian Nuclear Science and Technology Organization. He also serves as consultant and member of scientific advisory boards of several biopharmaceutical companies and venture capital funds. Dr. Shochat earned B.Sc. in Zoology and Physiology (1965) and M.Sc. in Physiology (1968) from the Hebrew University of Jerusalem, Israel and Ph.D. in Biochemistry and Protein Chemistry (1976) from LSU Medical Center, New Orleans, LA. He was a post-doctoral fellow in the Department of Biochemistry (1975-1978) and Sr. Research Associate at the Division of Experimental Pathology (1978-1983), the University of Kentucky Medical Center, Lexington, KY. In 1983 he participated in founding the Center for Molecular Medicine and Immunology at the University of Medicine and Dentistry of New Jersey, Newark, NJ, where he was an Associate Member until he joint Immunomedics, Inc. in 1984. From 1986-1992 Dr. Shochat served successively as visiting lecturer and adjunct professor at the Chemistry Department of Rutgers University Graduate School (Newark, NJ campus).


News for Friday, 10 August 2012 - www.implu.com

www.implu.com [cached]

SHOCHAT DAN, a major shareholder at KALOBIOS PHARMACEUTICALS INC


Management Team | KaloBios

kalobios.com [cached]

Dan Shochat, Ph.D.
Vice President and Head of Non-Clinical Development Dr. Shochat has served as our Vice President and Head of Non-Clinical Development since January 2004. Prior to this, he co-founded Celscia Therapeutics in 2003 and served as Executive Vice President and Chief Technical Officer before merging Celscia with KaloBios in 2004. Dr. Shochat has 28 years of experience in the biopharmaceutical industry and 34 years of involvement in research and development of antibodies and antibody conjugates for imaging and therapy. Dr. Shochat served as Vice President of Pharmaceutical Development at Deltagen, Inc. from 2001 to 2002. In 1995, Dr. Shochat was the first employee of Coulter Pharmaceutical, Inc. as Vice President of Research and Development, and subsequently was promoted to Senior Vice President and Chief Scientific Officer. At Coulter, he led the development and manufacturing of Bexxar, a novel centrally radiolabeled monoclonal antibody. In 1988 he joined American Cyanamid to establish the Biotechnology Development Section and led it until 1995. Prior to this, Dr. Shochat established the Product R&D Group at Immunomedics Inc. and directed it from 1984 to 1988. Dr. Shochat holds a Bachelor of Science in biology and a Master in Science in physiology from the Hebrew University in Jerusalem, Israel, and a Ph.D. in biochemistry from Louisiana State University Medical Center.


Scientific Advisory Board

www.modigenetech.com [cached]

Dan Shochat, Ph.D. led the development of Bexxar®, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma, which was approved by the FDA in June 2003.
At American Cyanamide Co., Dr. Shochat led the development, in collaboration with Celltech, of the first approved antibody-drug conjugate, Mylotarg®; Invented the technology and single-vial formulation, and then developed the FDA-approved in vivo tumor-imaging reagent CEA-Scan®. Dr. Shochat is currently Executive Vice President of Development of KaloBios, Inc. Formerly, Dr. Shochat was Director, Product R&D, Immunomedics; Director of Biotechnology Development at American Cyanamid Co.; Senior Vice President and Chief Scientific Officer Coulter Pharmaceutical, Inc.; Ph.D. in Biochemistry from L.S.U. Medical School in New Orleans, LA.


Kalobios Kalo: Gr, good; Bios: Gr, life

www.kalobios.com [cached]

Dan Shochat, Ph.D., Vice President, Head of Non-clinical Development
Dr. Shochat has over 22 years of experience in the biotechnology industry and is a pioneer in the antibody development arena. At Immunomedics, he led the team that developed the approved in vivo tumor-imaging reagent CEA-Scan. He joined American Cyanamid in 1989 to establish their biotechnology development capability and led the team that developed the first approved antibody-drug conjugate, Mylotarg. In 1995, Dr. Shochat became the first employee of Coulter Pharmaceutical, where he established a 'virtual development activity' managing the outsourcing of process development, manufacturing and quality systems by recruiting key experts in each area. He designed and established the process, formulation, and facility to commercially radiolabel the anti-B1 antibody at a 55 curie scale.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory